1. 1840PPreclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. (23rd October 2018) Authors: Brett, S; Yadavilli, S; Seestaller-Wehr, L; Bhattacharya, S; Jackson, H; Bi, M; Willoughby, J; Zhang, T; Liu, Y-B; Katlinskaya, Y K; Shi, H; Jing, J; Hahn, A; Speller, S; David Figueroa, D; Yu, J; Olive, D; Cragg, M; Mayes, P; Hoos, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 396OA multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer. (25th November 2018) Authors: Han, B; Li, K; Chu, T; Bi, M; Zhang, H; Yu, Y; Shi, J; Zhang, X; Chen, Z; Han, C; Bai, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1192PEvaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade. (23rd October 2018) Authors: Jackson, H; Bhattacharya, S; Bojczuk, P; Kilian, D; Seestaller Wehr, L; Hahn, A; Shi, H; Bi, M; Adam, M; Jing, J; Morley, P; Hopson, C; Paul, E; Hoos, A; Smothers, J; Srinivasan, R; Yanamandra, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗